MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10549-023-07108-6

Медицинская библиотека · Breast cancer research and treatment · 2023

The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer: a study of the SONABRE registry.

Lammers Senna W M, Thurisch Hannah, Vriens Ingeborg J H, Meegdes Marissa, Engelen Sanne M E, Erdkamp Frans L G, Dercksen M Wouter, Vriens Birgit E P J, Aaldering Kirsten N A, Pepels Manon J A E, van de Winkel Linda M H, Peters Natascha A J B, Tol Jolien, Heijns Joan B, van de Wouw Agnes J, Teeuwen Nathalie J A, Geurts Sandra M E, Tjan-Heijnen Vivianne C G

СтатьяПеревод в очереди

Аннотация

PURPOSE: This study determines the prognostic impact of body mass index (BMI) in patients with hormone receptor-positive/human epidermal growth factor receptor-2-negative (HR+/HER2-) advanced (i.e., metastatic) breast cancer (ABC).

METHODS

All patients with HR+/HER2- ABC who received endocrine therapy +-a cyclin-dependent kinase 4/6 inhibitor as first-given systemic therapy in 2007-2020 in the Netherlands were identified from the Southeast Netherlands Advanced Breast Cancer (SONABRE) registry (NCT03577197). Patients were categorised as underweight (BMI: < 18.5 kg/m2), normal weight (18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2), or obese (≥ 30.0 kg/m2). Overall survival (OS) and progression-free survival (PFS) were compared between BMI classes using multivariable Cox regression analyses.

RESULTS

This study included 1456 patients, of whom 35 (2%) were underweight, 580 (40%) normal weight, 479 (33%) overweight, and 362 (25%) obese. No differences in OS were observed between normal weight patients and respectively overweight (HR 0.99; 95% CI 0.85-1.16; p = 0.93) and obese patients (HR 1.04; 95% CI 0.88-1.24; p = 0.62). However, the OS of underweight patients (HR 1.45; 95% CI 0.97-2.15; p = 0.07) tended to be worse than the OS of normal weight patients. When compared with normal weight patients, the PFS was similar in underweight (HR 1.05; 95% CI 0.73-1.51; p = 0.81), overweight (HR 0.90; 95% CI 0.79-1.03; p = 0.14), and obese patients (HR 0.88; 95% CI 0.76-1.02; p = 0.10).

CONCLUSION

In this study among 1456 patients with HR+/HER2- ABC, overweight and obesity were prevalent, whereas underweight was uncommon. When compared with normal weight, overweight and obesity were not associated with either OS or PFS. However, underweight seemed to be an adverse prognostic factor for OS.

Для цитирования: Lammers Senna W M, Thurisch Hannah, Vriens Ingeborg J H, Meegdes Marissa, Engelen Sanne M E, Erdkamp Frans L G, Dercksen M Wouter, Vriens Birgit E P J, Aaldering Kirsten N A, Pepels Manon J A E, van de Winkel Linda M H, Peters Natascha A J B, Tol Jolien, Heijns Joan B, van de Wouw Agnes J, Teeuwen Nathalie J A, Geurts Sandra M E, Tjan-Heijnen Vivianne C G. The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer: a study of the SONABRE registry.. Breast cancer research and treatment. 2023. DOI: 10.1007/s10549-023-07108-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.